Balani Shanthi S, Sadiq Sanober, Jensen Chelsey J, Kizilbash Sarah J
Division of Nephrology, Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States.
Division of Nephrology, Department of Pediatrics, University of California, San Francisco, CA, United States.
Front Pediatr. 2023 Feb 20;11:1098434. doi: 10.3389/fped.2023.1098434. eCollection 2023.
Human cytomegalovirus (CMV) remains one of the most common opportunistic infections following solid organ transplantation in children. CMV causes morbidity and mortality through direct tissue-invasive disease and indirect immunomodulatory effects. In recent years, several new agents have emerged for the prevention and treatment of CMV disease in solid organ transplant recipients. However, pediatric data remain scarce, and many of the treatments are extrapolated from the adult literature. Controversies exist about the type and duration of prophylactic therapies and the optimal dosing of antiviral agents. This review provides an up-to-date overview of treatment modalities used to prevent and treat CMV disease in solid organ transplant (SOT) recipients.
人巨细胞病毒（CMV）仍然是儿童实体器官移植后最常见的机会性感染之一。CMV通过直接的组织侵袭性疾病和间接的免疫调节作用导致发病和死亡。近年来，出现了几种用于预防和治疗实体器官移植受者CMV疾病的新药物。然而，儿科数据仍然匮乏，许多治疗方法是从成人文献中推断而来的。关于预防性治疗的类型和持续时间以及抗病毒药物的最佳剂量存在争议。本综述提供了用于预防和治疗实体器官移植（SOT）受者CMV疾病的治疗方式的最新概述。
